Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Skin Neoplasms × encorafenib × Clear all

Phase

Status

Terminated 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 6 Colorectal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Skin Neoplasms 1 Pancreatic Neoplasms 1 Neurofibromatosis 1 1 Neoplasms 1 Neoplasm Metastasis 1 Lymphatic Metastasis 1 Lung Neoplasms 1 Hereditary Sensory and Autonomic Neuropathies 1 Hematologic Neoplasms 1 Gliosarcoma 1 Glioma 1 Glioblastoma 1 Brain Neoplasms 1 Astrocytoma 1

Interventions

Cyclophosphamide 11 fludarabine 8 aldesleukin 8 fludarabine phosphate 6 pembrolizumab 5 Nivolumab 4 Ipilimumab 4 Interleukin-2 4 dabrafenib 2 Vemurafenib 2 Biopsy 2 Aminolevulinic Acid 2 varlilumab 1 trametinib 1 tilsotolimod 1 spartalizumab 1 sotigalimab 1 sonidegib 1 smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic 1 glembatumumab vedotin 1 eprenetapopt 1 encorafenib 1 cemiplimab 1 cabozantinib 1 binimetinib 1 bempegaldesleukin 1 abobotulinumtoxinA 1 X-Rays 1 Tranexamic Acid 1 Tacrolimus 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05926960 2026-03-09

PORTSIDE

Pfizer

Phase 2 Terminated

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡